HK Inno.N Corp
KOSDAQ:195940
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
HK Inno.N Corp
Stock-Based Compensation
HK Inno.N Corp
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
HK Inno.N Corp
KOSDAQ:195940
|
Stock-Based Compensation
₩12.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Yuhan Corp
KRX:000100
|
Stock-Based Compensation
₩549m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Stock-Based Compensation
₩3.6B
|
CAGR 3-Years
291%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
HK Inno.N Corp
Glance View
HK inno.N Corp. engages in the provision of healthcare services. The company is headquartered in Chungju, Chungcheongbuk-Do. The company went IPO on 2021-08-09. The firm operates its business through three segments. The Prescription Drug segment is engaged in the manufacture and sale of hormone drugs, anticancer drugs, high blood pressure drugs, gastroesophageal reflux disease drugs, blood nutrient supplies, the circulatory system and others. The Health Beauty and Beverage (HB&B) segment is engaged in the manufacture and sale of products such as hangover relieving products, as well as health drinks and food products. The Other segment is engaged in the trademark royalties business and other services. The firm sells its products within domestic market and to overseas markets.
See Also
What is HK Inno.N Corp's Stock-Based Compensation?
Stock-Based Compensation
12.4m
KRW
Based on the financial report for Dec 31, 2024, HK Inno.N Corp's Stock-Based Compensation amounts to 12.4m KRW.
What is HK Inno.N Corp's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 1Y
-89%
Over the last year, the Stock-Based Compensation growth was -89%.
